Hisamitsu Pharmaceutical
Hisamitsu's headquarters in Tosu, Japan. | |
Native name | 久光製薬株式会社 |
|---|---|
Romanized name | Hisamitsu Seiyaku kabushiki gaisha |
| Company type | Public |
| TYO: 4530 NAG: 4530 FSE: 4530 | |
| Industry | Pharmaceutical |
| Founded | 1847 |
| Headquarters | Tosu, Saga, Japan Marunouchi, Chiyoda, Tokyo, Japan |
Area served | Worldwide |
Key people | Hirotaka Nakatomi (President and CEO) |
| Products |
|
| Revenue | JPY 150.63 billion (US$1.47 billion) (FY 2013) |
| JPY 21.35 billion (US$209.5 million) (FY 2013) | |
Number of employees | 2,949 (2014) |
| Website | global |
| Footnotes / references | |
The Hisamitsu Pharmaceutical Co., Inc. (Japanese: 久光製薬株式会社, Hepburn: Hisamitsu Seiyaku kabushiki gaisha), headquartered in Tosu and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug (OTC) products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology (TDDS) since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration (FDA).